Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of the preservative-free
fixed tafluprost-timolol combination to those of tafluprost and timolol alone. This study
will enroll patients who have ocular hypertension or glaucoma and who are using timolol or
prostaglandin.
The study medication period is 6 months, but the primary evaluation of efficacy is done at 3
months.